Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score Less Than 1: A Bayesian Meta-Analysis

Genitourinary Cancer

Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

J Natl Compr Canc Netw

Mahmoud N, Mustasam A, Miller J, Lakhram A, Hatoum F, Thompson ZJ, Kim Y, Souza GR, Johnson JS, Safa H, Spiess PE, Chahoud J

doi: 10.6004/jnccn.2026.7025

Gynecologic Cancer

Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials

Cancer Treat Rev

Vida R, Bartoletti M, Montico M, Pignata S, Baldassarre G, Ditto A, Zapelloni G, Rizzetto M, Lay L, Margherita P, Puglisi F

doi: 10.1016/j.ctrv.2026.103094

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Head and Neck Cancer

Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade

Clin Cancer Res

Kavanagh FG, Instrum RS, Boe LA, Eagan AJ, Scholfield DW, Finnegan EA, Wong RJ, Morris LG, Ow TJ, Wong W, Barker CA, Riaz N, Pulitzer MP, Busam KJ, Patel SG, Fetten J, Ganly I

doi: 10.1158/1078-0432.CCR-26-0123

Lung, Respiratory and Thoracic Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Lung Cancer

Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S

doi: 10.1016/j.lungcan.2025.108855

Head and Neck Cancer

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study

J Clin Oncol

Licitra L, Tahara M, Harrington K, Olivera Hurtado de Mendoza M, Guo Y, Aksoy S, Fang M, Csőszi T, Klochikhin M, Bueno de Oliveira T, Takahashi S, Yang MH, Swiecicki PL, Even C, Fayette J, Dutcus C, Okpara CE, Shen J, Benjamin K, Gumuscu B, Haddad RI, LEAP-010 investigators

doi: 10.1200/JCO-25-00570

Head and Neck Cancer

Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review

Adv Ther

Mojebi A, Tang Y, Keeping S, Merchant S, Bidadi B, Zheng D

doi: 10.1007/s12325-026-03604-5

Lung, Respiratory and Thoracic Cancer

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes

Cancer Treat Rev

Marinelli D, Citarella F, Torchia A, Pannu S, Aijaz A, Sisca L, Russano M, Fujiwara Y, Takada K, Nassar AH, Banna GL, Ricciuti B, Brunetti L, Santo V, Passaro A, Saw SPL, Li MSC, Addeo A, Ferrara R, Di Maio M, Mountzios G, Santini D, Maugeri-Saccà M, Vincenzi B, Acker F, Reckamp KL, Cappuzzo F, Naqash AR, Cortellini A

doi: 10.1016/j.ctrv.2026.103159

Genitourinary Cancer

Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

Int J Cancer

Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J, Ansari J, Zeppellini A, Taha T, Buti S, Ürün Y, Scagliarini S, Li H, Sunela K, Park SH, Rizzo M, Zgura A, Chiari R, Seront E, Catalano M, Ghosn M, Filosa A, Soares A, Massari F, Monteiro FSM, Grande E, Porta C, Bracarda S, Santoni M

doi: 10.1002/ijc.70228

Related content

Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study

Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes

Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)